Beyond MYCN, NB exhibit few recurrent potentially druggable targets and, for this reason, there is an ever-high need to find new potential targets that can help in overcoming this cancer and in preventing the emergence of acquired resistance (59). The gene discussed is MYCN; the disease is neuroblastoma.